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ABSTRACT
This article deals with the incorporation of patient-reported
outcomes (PROs) into clinical trials and focuses on issues
associated with the interpretation and reporting of PRO data.
The primary focus and context of this information relates
to the evidentiary support and reporting for a labeling or
advertising claim of a PRO beneﬁt for a new or approved
pharmaceutical product. This manuscript focuses on issues
associated with assessing clinical signiﬁcance and common
pitfalls to avoid in presenting results related to PROs. Spe-
ciﬁcally, the questions addressed by this manuscript involve:
What are the best methods to assess clinical signiﬁcance for
PROs? How should investigators present PRO data most
effectively in a Food and Drug Administration (FDA) appli-
cation? In labeling or in a scientiﬁc publication? Guidelines
for interpreting clinical signiﬁcance of PROs and for compre-
hensively reporting on the methods, measures and results of
clinical trials that incorporate PROs are important for clini-
cians, regulatory agencies, and most of all to patients. Clear
speciﬁcations for considering a ﬁnding on a PRO measure, as
clinically meaningful, need to be determined by instrument
developers and psychometricians; they need to be reported
for all clinical trials involving PRO end points. Clinical trial
reports need to be comprehensive, clear, and sufﬁcient to
enable any reader to understand the methods, PROmeasures,
statistical analysis, and results.
Keywords: clinical signiﬁcance, clinical trials, health-related
quality of life, minimal important differences, patient-
reported outcomes, statistical analysis.
Introduction
This article focuses on issues associated with the inter-
pretation and reporting of patient-reported outcome
(PRO) data. The primary focus and context of this
information relates to the evidentiary support and
reporting for a labeling or advertising claim of a PRO
beneﬁt for a new or approved pharmaceutical product.
Nevertheless, the issues and recommendations dis-
cussed are not unique to pharmaceutical and regula-
tory applications. Therefore, the information may be
generalizable to other clinical trials and settings that
include PRO end points. For this article, we assume
that the PRO is an important effectiveness end point in
the study and that the intent of the clinical develop-
ment research program is to achieve a labeling or
promotional claim. We also assume that the PROs
were selected based on strong rationale, that the
instruments selected are credible and relevant, and
have evidence supporting systematic development and
psychometric qualities in the particular study popula-
tion [1]. See other articles in this series regarding best
practices for PRO instrument development and psy-
chometric evaluation.
Ensuring fair and complete reporting of PRO end
points based on a clinical development program for a
new medication is important. The focus should be
primarily on prespeciﬁed PRO end points and those
end points that reach statistical and clinical signiﬁ-
cance criteria. Nevertheless, even with psychometri-
cally sound measures, a priori speciﬁcation of primary
PRO end points, and well-designed clinical trials,
unexpected patterns of ﬁndings may be observed. In
these situations, it is important to report all of the
prespeciﬁed PRO end points, whether they are sup-
portive or nonsupportive of the treatment. Here, we
focus on interpreting statistically and clinically signiﬁ-
cant PRO ﬁndings and the effective reporting and
presentation of PRO data.
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What Are the Best (Alternative) Methods to
Assess the Interpretation of Clinical
Signiﬁcance for PROs?
Deﬁnitions and Methods of Minimal
Important Differences
The minimal important difference (MID) has been
deﬁned as the smallest change in a PRO measure that
is perceived by patients as beneﬁcial, or that would
result in a clinician considering a change in treatment
[2]. The term MID has been widely adopted but the
use of the term may be problematic in that it has been
interpreted in many different ways.
Several anchor-based and distribution-based
methods have been used to determine the MID for
PRO measures [2,3]. Nevertheless, the current situa-
tion for determining the MID is evolving, and no clear
consensus exists as to the recommended approach for
determining the MID [2]. The usual approach is to
estimate the MID using several anchor-based methods
with relevant clinical or patient-based indicators,
examine various distribution-based estimates (i.e.,
effect size, standardized response mean, standard error
of measurement [SEM]), and then triangulate on a
single value or small range of values for the MID.
Conﬁdence in a speciﬁc MID value evolves over time
and is conﬁrmed by additional research evidence. We
all need to realize and accept that aspects of human
measurement include some error and that no PRO
measure is perfect and should not be expected to be
perfect to be used in clinical research. Additionally, it is
likely that the MID value varies by the population in
which the PRO is used and that there is no single MID
value for a PRO instrument across all applications and
patient samples. The anchor-based methods for deter-
mining MID are preferred, with the distribution-based
approaches providing supportive evidence.
Anchor-Based Methods
The anchor-based approaches use an external indica-
tor, either clinical or patient-based, to assign subjects
into several groups reﬂecting no changes, small posi-
tive changes, large positive changes, small negative
changes, or large negative changes in clinical or health
status [2–4]. The anchors can be clinical (hematocrit,
American College of Rheumatology (ACR) response,
clinician-rated change), or patient-based, such as
global ratings of change or actual changes in PRO
measures that have previously demonstrated MID and
have been demonstrated to be responsive in the patient
population. Regardless of the selected basis, investiga-
tors need to collect data to understand the practical
value of scores based on the relationship to clinical
outcomes (e.g., morbidity and death), patient behavior
(e.g., adherence to medication use and resource utili-
zation), and consequences on work (loss of productiv-
ity or working days).
We recommend that MID and clinical signiﬁcance
be based on multiple independent anchors. Selecting
anchors should be done using criteria of relevance for
the disease indication, clinical acceptance and validity,
and evidence that the anchors have some relationship
with the PRO measure. One important test conducted
before calculating an MID is to determine the strength
of the association of the anchor measure with the
MID. An anchor that has a very low or even moderate
correlation may provide misleading information in
deﬁning what is important to patients.
In general, patient-based anchors are considered
important for estimating the MID for PROs. The
degree of change observed may depend on the direc-
tion of change, and it may not be of consistent
magnitude for those who deteriorate and those who
improve. In addition, investigators need to consider
what constitutes a clinically signiﬁcant change in the
target disease. For example, in some diseases (e.g.,
cancer, chronic obstructive pulmonary disease
[COPD]) for which the goal of treatment is to maintain
rather than improve function, clinically relevant
change may be related to demonstrating a lack of
disease progression in a treated group compared with
an untreated group which is expected to deteriorate. In
these cases, the clinical signiﬁcance of differences
between those who maintain clinical status and those
who deteriorate may be of interest.
Distribution-Based Methods
The distribution-based methods include various forms
of the effect size, standard response mean, and SEM
methods [2–4]. Basically, these methods provide
descriptive statistics on the magnitude of change
observed in a study in standard deviation units or, in
the case of SEM, reliability-adjusted standard devia-
tion units. For example, the observed effect size may
depend on the level of change found in a particular
study, the impact of intervention used, the character-
istics of the population being studied (e.g., disease
severity, gender, sex, age), and the representativeness of
the population studied. Effect sizes may vary widely
according to condition. Small effect sizes may be mean-
ingful to patients with severe disease, whereas only
moderate to large effect sizes may be important to
patients with milder disease. Although these indicators
can be informative as to how large the change is, they
do not provide any indication of whether the observed
change is important to either patients or clinicians.
Determination of Change over Time
Several methodological issues and open questions
remain to be answered in regard to the MID. Research-
ers need to understand the study design used to estab-
lish an MID for a PRO [5]. For example, they need to
determine whether the MID was based on change
within a population over time or calculated in a clini-
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cal trial looking at change over time in a treatment
group correcting for changes in a placebo group. In the
ﬁrst case, the MID may actually reﬂect a minimally
important change within a group. One might want to
apply the minimal change determined in an observa-
tional cohort to deﬁne what constitutes a minimal
difference between treatment groups. This MID value
can be used to evaluate within-treatment group or
between-treatment group changes in the clinical trial
population (e.g., calculating the percent of patients in
each treatment group meeting the MID). Nevertheless,
there is some uncertainty whether MIDs derived from
observational studies can be applied in clinical trials
which focus on mean differences between treatment
groups. These issues have not been ﬁrmly resolved and
little rigorous research has been applied.
Variation Based on Impact and Population
TheMID of a PRO can vary according to the impact of
the intervention and characteristics of the population
being studied (e.g., disease severity, gender, sex, age)
[6]. An MID value calculated for a PRO measured in a
less severely diseased patient population may be differ-
ent from the MID value calculated in a more severely
diseased group. Even if an MID has been established
within a broad range of patients and, hence, reﬂects a
generally applicable MID, the use of the MID value to
establish meaningful change in a given population may
not be valid.
Even the global question used to anchor a PRO and
how the data are combined may affect the calculation
of an MID for that measure. A study of two different
global questions showed different MIDs for the same
PRO. Additionally, this same study demonstrated that
the MID differed between groups of patients who
improved and those who deteriorated over time even
with treatment [7]. This ﬁnding is contrary to ﬁndings
in some observational studies in which the MID for
improvement and deterioration were the same [8].
Other researchers have observed asymmetry in im-
proving and worsening groups [9,10].
Instrument-Speciﬁc Evidence from Published Studies
For research topics in which PROs may be more
common in clinical trials, review and synthesis of pre-
viously reported data from clinical trials may help
inform the choice of an MID. As a PRO instrument is
incorporated into more clinical trials, for example the
St. George’s Respiratory Questionnaire (SGRQ) [11]
in COPD studies, more evidence emerges on respon-
siveness and the value of the MID. Jones [12] reported,
based on a review of completed clinical trials, that the
MID for the SGRQ total score is 4 points. Conducting
systematic reviews and meta-analyses of responsive-
ness and observed changes in PRO scores based on
multiple clinical trials may be possible. Information
from such work can help further understanding of the
clinical signiﬁcance and MID of PRO measures.
Triangulation
The use of multiple methods to determine the MID for
a PRO instrument in a speciﬁc patient population typi-
cally yields a range of values for the MID. This is the
essence of triangulation, which is, examining multiple
values from different approaches and converging on a
small range of values. We recommend that the different
MID estimates be graphed to depict the range of esti-
mates. To identify a single MID value (or narrow the
range of MID values), we also recommend that the
anchor-based estimates be assigned the most weight
and experience from clinical trials be used to further
support and perhaps further narrow the range of
values. This MID range would evolve over time as
more evidence becomes available from clinical studies.
Interpretation of the MID from different anchors
should also take into account the proximity of the
anchor to the target PRO measure; that is, investiga-
tors should assign more importance to MIDs generated
from closely linked concepts than to those from widely
disparate concepts. The distribution-based methods
can provide additional support, but they should not be
the sole criteria for estimating anMID. In cases lacking
any suitable anchor, however, the distribution-based
approach may the best available method [13].
To arrive at a single MID value, we recommend that
analysts conduct a systematic consensus process, based
on Delphi methods, involving several clinicians and
health outcome researchers. No consensus exists as to
how much data are needed as supportive evidence for
the MID of a PRO instrument. Clearly, more data and
evidence are better, but a single, generalizable study
with multiple patient-based and clinical anchors may
be sufﬁcient. If there are a range of MID estimates for
a PRO instrument, based on relevant anchors, the
investigator will need to select a priori a value for the
clinical study and provide a rationale for selecting this
MID value.
As with other aspects of construct validity, respon-
siveness and the MID value are conﬁrmed based on
accumulating evidence from multiple studies and, with
additional data, we can be more conﬁdent in the MID
value. It is unlikely that a single MID could apply to all
applications and patient populations. For example, the
MID derived for an asthma-speciﬁc quality of life
measure in trials involving patients with only mild to
moderate asthma may not be applicable or appropriate
for clinical trials comparing an add-on treatment for
patients with moderate to severe asthma [14].
Statistical and Clinical Signiﬁcance of Prespeciﬁed PRO
End Points over Time
Interpreting the PRO ﬁndings from clinical trials
should be based primarily on those PRO end points
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speciﬁed a priori that achieve statistical signiﬁcance
and that also meet clinical signiﬁcance criteria. Clinical
signiﬁcance is most often based on a clearly speciﬁed
MID for the PRO score that is relevant for the target
population and study context. The primary PRO end
points should be clearly stated in the statistical analysis
plan and protocol. Other secondary PRO end points
may be discussed, but these outcomes are of secondary
importance and may be used to further support the
primary PRO ﬁndings.
Making statements about PRO differences between
treatment groups is most often done by comparing
mean changes from baseline, modeling mean scores
over time (as in a mixed model analysis of variance), or
comparing the percentage of subjects in each treatment
group exceeding an a priori MID. No consensus exists
on the best way among various possible approaches, to
compare treatment differences on a PRO end point. In
general, the results of different methods are similar, but
this pattern is not always observed.
Treatment differences on mean changes from base-
line that exceed the MID for the PRO instrument do
not imply that all subjects in the better treatment
group achieved these improvements. A distribution of
change scores exists such that some patients exceeded
the MID value and others failed to achieve it. On
average, however, the members of the treatment group
with the higher mean change scores have done better
than those in the group reporting lower mean change
scores.
Often, to assist clinicians in interpreting PRO dif-
ferences, analysts report and compare the percentages
of subjects exceeding the MID value for the PRO. For
example, a recent meta-analysis of the effects of oma-
lizumab in moderate to severe asthma found a 1.6- to
2.0-fold increase in moderate (>1 point) and a 1.8- to
2.1-fold increase in large (>1.5 points) improvements
in overall Asthma Quality of Life Questionnaire
(AQLQ) scores [14]. These differences were apparent
despite observing differences between active agent and
placebo in the mean changes from baseline of less than
the 0.5-point MID for the AQLQ. Clearly, there are
real differences in AQLQ outcomes seen across these
clinical trials, but differences between the trial popu-
lations and the asthma population used to determine
the MID for the AQLQ may in part explain these
ﬁndings [6].
Number Needed to Treat
Some outcomes researchers have suggested that the
number needed to treat (NNT) may be an effective way
to express clinical and PRO results that may be easier
for clinicians to understand and interpret [15]. Basi-
cally, the NNT is the relative proportion of patients
who achieved important PRO beneﬁts from treatment.
NNT values indicate the number of patients that
would need to be treated to achieve the PRO beneﬁt.
Lower NNTs suggest more effective treatments. Previ-
ous research has demonstrated a relationship between
the proportion of patients beneﬁting from treatment,
the NNT, and the effect size [16]. Therefore, reporting
the percentage of subjects by treatment group who
beneﬁt on a PRO end point may be just as effective as
reporting the NNT. Note that the NNT still depends
on an MID that has been developed for a PRO which
is limited (as stated above) by methodology and
patient population differences.
Reporting PRO Evidence and Studies
Patient-reported outcomes, along with clinician-
reported outcomes, laboratory tests, and device mea-
surements, are collected in clinical trials to evaluate the
effectiveness of treatments. Instruments within each of
the types of measurements have unique sets of charac-
teristics that make them relevant for use in a given
trial. Guidelines have been proposed to assist in the
preparation of manuscripts and presentation of data.
For PRO measures, in particular, guidelines have been
proposed by Fayers and Machin [17], Revicki [18],
Staquet et al. [19,20] and Sloan et al. [21].
In this section, we go beyond previously published
guidelines by specifying the detailed type of informa-
tion needed to describe adequately PRO instrumenta-
tion used in a study. Complete information is needed
about the relationships among each instrument, the
study population, and the interventions, as well as
data collection procedures, methods of analysis, and
methods of interpretation, for understanding the ﬁnd-
ings and for generalizing the results beyond any par-
ticular study.
By following the detailed reporting of information
recommended here, users can compare PRO informa-
tion across various studies, whether conducted as part
of a submission to the Food and Drug Administration
(FDA) or for other purposes. Consistent reporting can
also lead to the creation of an evidence-based data set
that can be used to support the construct validity
of PRO instruments in a variety of settings. This in-
formation might simplify the FDA submission and
approval process as well as contribute to a more
informed instrument selection process in the future.
Description of the Instruments Used
A description of each PRO instrument used in any trial
is critical for understanding the outcomes. In most
publications, this information is minimal, consisting
of the name of the instrument with key references to
its development and to documentation of its measure-
ment properties. This is typically accompanied by a
statement that the instrument has been administered,
scored, and analyzed according to the developer’s
documentation. Providing minimal information about
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a PRO instrument in the Material andMethods section
is acceptable only in trials that use an instrument
without any modiﬁcation.
A minimal description is satisfactory when the PRO
instrument has been well documented by its developer
and widely used, such as the St. George’s Respiratory
Questionnaire (SGRQ) [11] and the SF-36 [22].
Minimal information is insufﬁcient, however, for
instruments with little or no formal documentation.
For these tools, sufﬁcient information to be described
in the Materials and Methods section includes the
minimal details (given above) as well as domain
names, recall period, and methods of scaling and
scoring. All modiﬁcations to the original tool and/or
conditions for use, e.g., changes in item wording,
recall period, and scoring method, should be fully
described to clarify interpretation and comparability
of ﬁndings. A copy of the instrument should appear in
the cited references, if possible, be readily available at
a permanent website, or supplied by the authors on
request.
Ideally, the Materials and Methods section should
include all of the minimal and sufﬁcient information as
well as a copy of the instrument, in either the text or an
appendix. This need not be in camera-ready format
but, rather, may be in reviewable form that includes
the item stem, response options, and recall period.
With ready access to the tool, the reader can evaluate
the instrument’s content within the context of the trial
and thus interpret the ﬁndings meaningfully.
If an instrument has been endorsed by a profes-
sional organization, such as the American College of
Rheumatology, this point should be noted along with
an instrument’s description and taken as indication of
the relevance of an instrument’s content. For example,
the ACR response criteria incorporate several PROs
[23,24]. Endorsement also implies widespread use
with results contributing evidence to support an instru-
ment’s construct validity. If an instrument lacks
professional endorsement, then including a review
version of the instrument in the article will help the
reader determine its appropriateness. Also, without
an endorsement and/or widespread use, evidence will
need to be provided as to an instrument’s validity for
use in a particular study population.
Although reporting minimal and sufﬁcient informa-
tion seems basic, it is easy to ﬁnd articles that cite
incorrect instrument names and references and fail to
describe changes in wording and/or scoring proce-
dures. Most frequently, however, authors name and
reference an instrument, but provide no information as
to the conditions of its use. For example, in a review of
approximately 100 articles reporting the use of either
the General Well-Being or the Psychological General
Well-Being Index [25] in clinical trials, 55% provided
less than minimal information about how the instru-
ment was actually used [26].
Description of the Study Population
Investigators should explicitly state all inclusion and
exclusion criteria for the trial population; they should
also describe the settings and locations of clinical trial
sites. The same guidelines that apply to reporting clini-
cal trial data involving clinical end points should also
apply to studies with PRO end points. The external
validity or generalizablity of PRO results should be
apparent from the information provided regarding the
study population. The inclusion and exclusion criteria
deﬁne the study population and provide necessary
information for understanding the characteristics of
the study population.
Description of the Intervention
Details of the interventions intended for each group
should be stated including the method, timing, and
duration of treatment administration. Authors should
describe the treatment given to the control group
(more than merely stating that a group received a
control regimen or “standard of care”), and they
should provide information on the placebo treatment
(if a placebo was used). Finally, they should state
whether the treatment was masked (i.e., double-blind)
or open label, as this may affect evaluation of
effectiveness.
In addition, specifying the course of treatment is
crucial so that the time points that the PRO instru-
ment(s) was (were) administered can be examined in
the context of treatment impact. From the description
of the treatment(s) being evaluated and the timing of
the PRO measurements (e.g., at baseline and weeks 2,
4, and 8), the relationship between treatment response
and the likely ability of the instrument to have detected
any change in status should be clearly understandable.
For example, short reference periods (e.g., 4 or
24 hours) are better suited for assessing the impact of
migraine treatment than are longer periods (e.g.,
1 week or 1 month).
Data Collection Procedures
PRO instruments, when used in clinical trials, can be
interviewer administered or self-administered either at
the site of care by postal questionnaire, by telephone
through an interactive voice recognition system, or via
electronic data capture. Analysts should disclose the
conditions of the administration site (e.g., a standard-
ized location free of distractions) and any formatting
speciﬁc to the study (e.g., large scale print to accom-
modate elderly persons with low vision or electronic
forms of data capture). If the PRO measure was
interviewer-administered, either in person or via the
telephone, the extent to which interviewers were
trained should be speciﬁed. Information on standard-
ized training of study coordinators or patients (e.g.,
training videos) and use of practice diaries during the
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placebo run-in period should also be provided. Such
detail is important for understanding the nature of
missing data and incomplete responses and potential
sources of bias.
If the procedures used in the trial differ from those
used in the development of the instrument then steps
used to validate the alternative method of administra-
tion should be described or referenced. Although spon-
sors may use PRO data collected in a Phase III clinical
trial to both validate a method of administration and
evaluate treatment efﬁcacy, they run the risk of not
being able to use the PRO results for making a claim if
the validation is unsuccessful. Thus, sponsors are ill
advised to use a pivotal trial for PRO validation pur-
poses. This same advice applies to using PRO data
from a Phase III study to validate initially any aspect of
an instrument that is also to be used as a trial end
point. Developers can use clinical trial data as support-
ive evidence for the psychometric properties of a PRO
but an independent validation study or another pub-
lished study of the end point would ideally be available
if sponsors intend for the PRO to be a primary end
point.
Sample Size Determination
If a PRO is the primary end point, then the Materials
and Methods section needs to state the methods and
information used in determining the sample size; this
requirement is similar to that for presenting equivalent
information for a non-PRO end point. It is especially
important to cite the source of the MID that is used
so that its relevance to the current study is clear. With
the increasing use of PROs in clinical trials, estimates
of MID are more readily available from published
sources. The power needs to be stated as well as any
effort to oversample to account for anticipated drop-
outs, for those who prove to be ineligible, for key
subgroups, or for missing data.
Many PRO instruments consist of multiple domains
and subdomains, unlike laboratory tests, device mea-
surements, and many clinician-rated assessments. Even
if investigators intend to use a summary score (e.g., the
Health Assessment Questionnaire Disability Index),
the FDA may evaluate the subdomains. To accommo-
date this regulatory analysis, a larger sample size might
be advisable. If the sponsor decides to use this strategy,
the investigators should clearly state this point in the
methods section.
Statistical Methods
In addition to sample size calculations, the Materials
and Methods section needs to summarize the analysis
plan to be used with the PRO data. The use of para-
metric or nonparametric methods needs to be stated. If
a summary score is to be used to characterize patient
response, the derivation of the score should be
described and assumptions that might effect the inter-
pretation of the ﬁndings outlined. Ideally, sensitivity
analyses will be proposed to test the robustness of the
assumptions and the ﬁndings summarized. Computer
programs used in the scoring and analysis should
be named and referenced. Procedures for handling
missing data need to be stated and deviations from the
instrument developer’s speciﬁc instructions, when
available, should be justiﬁed [27].
Presentation and Interpretation of Findings
Clear and thorough presentation is essential because
PRO data provide the only statement of the patient’s
perspective on treatment impact. In addition, publica-
tion of the PRO data builds evidence to support the use
of an instrument in a variety of populations and set-
tings. That is, published ﬁndings help establish an
instrument’s construct validity.
Clinical trial data generally appear in tables or
annotated ﬁgures. Tables are essential for presenting
descriptive statistics that can be used by others to
calculate estimates of effect sizes and perhaps other
types of responsiveness statistics. This information
should be presented for all PROs used in the clini-
cal trial. Thus, PRO data need to be made publicly
available, whether in journals or as part of a website
of ﬁndings (perhaps as part of http://www.
ClinicalTrials.gov).
Figures can be used to show relationships between
PRO and clinical data. For example, Teeter et al. [28]
used a scatter plot to show the absence of a relation-
ship between FEV1 and total symptoms, thus illustrat-
ing the unique contribution of PRO data. Such plots
can be more informative than a summary statistic such
as a correlation coefﬁcient. Bar charts or line drawings
are also useful for showing either scores between
groups at a particular time point or change from base-
line scores. In these graphs, means, standard devia-
tions, and sample sizes should be given to allow the
reader to check for statistical signiﬁcance or calculate
responsiveness statistics. Charts without data are
unacceptable unless the data are presented in accom-
panying tables.
For investigating the relationship between treat-
ment groups in a PRO end point, the FDA in a recent
guidance document [29] suggested a cumulative distri-
bution plot (see page 19 in [29]) to supplement a table
of sample sizes, means, standard deviations, and/or
P-values for investigating differences between treat-
ment groups. A cumulative distribution plot shows
the distributional properties of the observed PRO
end point data not readily extracted from a table of
summary statistics. While a useful proposal, we
present alternative graphics which may be easier for
nonstatisticians to read (Fig. 1). A more detailed com-
parison of these alternative graphics is forthcoming.
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Complete disclosure about the amount and type of
missing data is imperative to the veracity of study
results. Presenting a CONSORT diagram is a concise
and complete method that has gained favor in recent
years [18,30]. It delineates what happened to every
person in the study from initiation to completion
and provides sample sizes for the various analytical
datasets (efﬁcacy, safety, etc.). Alternatively, or comple-
mentarily, a table of the amount of missing data should
be included to identify the exact number and propor-
tion of missing data that occurred for each end point.
Authors should comment about the amount of data
that they consider be missing at random or missing
owing to some systematic inﬂuence.
In reporting missing data, we recommend that
authors include the following information: number of
patients potentially able to provide data, number of
patients who died, and number of patients who failed to
provide data butwere alive. This gives a clear indication
of the proportion of patients who truly failed to provide
data when they might have and indicates the degree to
which missing data could have been avoided or may
have inﬂuenced results. It also allows for an examina-
tion of differential dropout between treatment arms.
PRO data are usually one of several types of data
collected in a clinical trial; other types include
clinician-reported outcomes, laboratory tests, and bio-
metric measures. Together, ﬁndings from these sources
yield a composite picture of treatment efﬁcacy and
effectiveness. Relationships between the types of indi-
cators need to be presented in a straightforward way
that will be readily understandable.
For transparency, all results should be presented.
What happens when there is a mix of positive and
negative PRO results for an experimental treatment?
For example, say a treatment group reported less
fatigue (primary end point) but more diarrhea (second-
ary end point) than the control group. Interpreting
such results will only be approachable on a case-by-
case basis. The decision ultimately has to ﬁt with the
concept for the label claim. An analogy here is the
listing of all potential adverse events that appear
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reported outcome.
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during a clinical trial. It is not unreasonable therefore
to suggest that any PRO domain that demonstrates a
beneﬁcial result might be included in a label claim or
promotion as a potentially positive effect of a treat-
ment, but that all other results, whether or not they are
beneﬁcial should also be presented to provide a full
picture of the effects. The PRO labeling claim should
be based on the a priori speciﬁed domains and whether
between-group differences were statistically and clini-
cally signiﬁcant for these speciﬁed domains. Neverthe-
less, unexpected PRO ﬁndings, either positive or
negative, may be seen in the secondary PRO end
points, and these results may be informative to clini-
cians and patients.
Discussion
Guidelines for interpreting clinical signiﬁcance of
PROs and for comprehensively reporting on the
methods, measures and results of clinical trials that
incorporate PROs are important for clinicians, regula-
tory agencies, and, most of all, for improving the
health care for patients. Clear speciﬁcations as to what
is considered a clinically meaningful ﬁnding on a PRO
measure need to be determined by instrument devel-
opers and psychometricians, and need to be reported
for all clinical trials involving PRO end points. The
reporting of clinical trial methods and ﬁndings need to
be comprehensive, clear, and sufﬁcient to enable any
reader to understand the methods, PRO measures,
analytic plans, and results. Clinical trials including
PRO end points may be used for regulatory submis-
sions to achieve labeling or promotional claims and/or
to report on outcomes that are more meaningful to
patients than the usual clinical end points, such as
visual acuity or tumor response.
Summaries of PRO data collected in a clinical trial
may be more detailed for an FDA submission than for
a journal submission where page restrictions may limit
the information provided. In either case, however,
basic instrument-speciﬁc PRO data should be pre-
sented so that they can be used to build an evidence
base for supporting the PRO labeling and for estab-
lishing construct validity and generalizability of ﬁnd-
ings. This evolving database is invaluable for
understanding the relevance and validity (including
responsiveness) of the PROs, and will help guide future
clinical studies.
For all PRO instruments cited in product labels,
a permanent, publicly accessible repository should
be maintained either by the FDA (as part of the label
information on the Drugs@FDA website: [http://
www.accessdata.fda.gov/scripts/cder/drugsatfda/] or
by the National Library of Medicine on the http://
www.ClinicalTrials.gov website. This repository
should contain a reviewable copy of each instrument,
the user manual, documentation of reliability, validity,
and responsiveness, as well as references to
instrument-speciﬁc clinical trial ﬁndings. Submissions
to this repository should be a mandatory requirement
for making claims based on a PRO instrument regard-
less of whether the instrument is speciﬁcally named in
the label. Availability of this detailed information will
help researchers and clinicians understand and inter-
pret ﬁndings and at the same time respond to critics’
concerns about the perceived complexity of PRO
measures.
The discussion on presentation need not signiﬁ-
cantly lengthen the Materials and Methods section of
a journal article, especially if PRO instruments are
used as developed and documentation about an instru-
ment’s development and measurement properties are
publicly available. In this case, much of the required
detail can be provided through a comprehensive list of
references. When documentation is unavailable from a
public source, then conditions of use of a PRO in trials
intended for supporting a product claim through the
FDA should be that 1) the developer/sponsor make
the information available for public review; and 2) the
regulator provide the access if the developer/sponsor is
either unable or unwilling to provide this information.
Clearly, full disclosure of information on the develop-
ment, psychometric characteristics, and performance
of PRO instruments in clinical trials is useful for
reviewers and clinicians, and perhaps even most of all
patients.
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